• AG9601
    Share

Trial Status

Completed

Cancer Type

Stomach Cancer

Protocol Title

A phase II feasibility study of pre-operative and post- operative chemotherapy using epirubicin, cisplatin and protracted venous infusion fluorouracil (ECF) in patients with advanced but operable gastric cancer.

Purpose of the Study

Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.

Principal Investigators

Prof Michael Findlay
Dr David Storey

Funding

Pharmacia Pty Limited (Australia)
NHMRC Clinical Trials Centre (Australia)

DETAILED INFORMATION AVAILABLE

Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) here

Trial Status

Completed

Cancer Type

Stomach Cancer

Publication Reference

Findlay M, Storey D, Gebski V, Hargreaves C, Cullingford G, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Yuen J, Dhillon H, Della-Fiorentina S, Richardson G, Truskett P, Goldstein D; on behalf of the AGITG. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. Australian and New Zealand Journal of Surgery 2007; 77(4): 247–252.

Conference Presentation Reference

Cullingford G, Findlay M, Storey D, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Gebski V, Dhillon H. A phase II feasibility study of preoperative and postoperative chemotherapy (epirubicin, cisplatin and 4FU) in patients with advanced but operable gastric cancer. American Society of Clinical Oncology Annual Scientific Meeting; 18–21 May 2002; Orlando.

Aim

Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.

Principal Investigator

Professor Michael Findlay, Medical Oncologist, Auckland Hospital, NZ
Dr David Storey, Upper GI Surgeon, Royal Prince Alfred Hospital, NSW

Funding

Pharmacia Pty Limited (Australia)
NHMRC Clinical Trials Centre (Australia)